F10 and atrial fibrillation: In the subanalysis of the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial, the edoxaban concentration was consistently lower in Asians than in non-Asians, regardless of whether the edoxaban dose was adjusted (Chao et al., 2019).